N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation

Sponsor: The University of Texas at Dallas • ClinicalTrials.gov ID: NCT07534397

Registry updated: 2026-09-16
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this research study is to examine the effects of transcranial Direct Current Stimulation (tDCS) on verbal retrieval and cognition and sensorimotor control and to determine if tDCS can be used as a way to improve retrieval, sensory, and motor abilities in individuals with Parkinson's disease (PD).

Interventions

  • transcranial direct current stimulation (Device)
    Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
  • Sham transcranial direct current stimulation (Device)
    Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.

Eligibility criteria

Inclusion Criteria: * Diagnosed with PD having a verbal fluency deficit based on neuropsychological test (T-score \< 40 or a T-score \<-1.0 SD below the average T-score): Semantic Object Retrieval Test (SORT), COWAT (both letter and category fluency), Boston Naming Test (BNT), Rey Auditory Verbal Learning Test (RAVLT) * 50 - 90 years old * Capable of understanding and signing an informed consent (able to answer consent comprehension questions) * Fluent in speaking and reading English Exclusion Criteria: A potentially study-confounding, tDCS-contraindicated, or EEG-contraindicated psychological, neuropsychiatric, neurological, or other medical issues: * Montreal Cognitve Assessment (MOCA) score \<23, unless an accompanying study partner/caregiver is with them and we can obtain the written consent of both the participant and the participant's accompanying study partner/caregiver (i.e., the participant's spouse, adult child, parent, or adult sibling); * history of seizures; * unexplained episodes of loss of consciousness (as these may be related to brain alterations or epilepsy); * suffering from severe or frequent headaches; * unstable or uncontrolled neuropsychiatric illness; * severe traumatic brain injury (based on the Ohio State TBI Identification; Method); * brain tumor; stroke; present drug abuse/misuse; * brain tumor; * serious or life-threatening diseases, including congestive heart failure, chronic obstructive pulmonary disease, or active malignancy; * Huntington's disease; * stroke; * cranial implants or skull defects that affect tDCS administration; * implanted brain medical devices, including, deep brain stimulators (DBS); * implanted pacemakers; * any electrically, magnetically, or mechanically activated implants; * cardiac, neural, or medication implants; * vascular clips or other electrically sensitive support systems in the brain; * damaged skin at the sites of stimulation (the device should only be used on healthy, intact skin, as wounds may alter resistance to current); * skin conditions such as dermatitis, psoriasis, or eczema; * pregnant women; * diagnosis of just dysarthria; Use of medications that interact with or potentially interact with tDCS or EEG effects: * anti-convulsants; * carbamazepine; * sulpiride; * pergolide; * lorazepam; * rivastigmine; * dextromethorphan; * D-cycloserine; * flunarizine; * ropinirole; * citalopram; * stimulants; Additionally, non-English speakers will be excluded because not all of the screening forms, questionnaires, and tests are available in languages other than English.

Conditions

PARKINSON DISEASE (Disorder)

Locations

  • Callier Clinical Center, The University of Texas at Dallas — Richardson, Texas, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record